News and updates
October 1, 2024
AstronauTx Appoints Jane Rhodes as Chief Executive Officer and Expands Executive Team
September 30, 2024
Aktis Oncology Announces $175 Million Oversubscribed Series B Financing
April 11, 2024
MPM BioImpact Appoints Frank Neumann, M.D., Ph.D., Distinguished Expert in Clinical Development, as Entrepreneur Partner
February 26, 2024
WSJ: Investors Flock Back to Biotech After a Long, Cold Spell – Featuring Chris Bardon
February 23, 2024
Frontier Announces Oversubscribed $80 Million Series C
February 15, 2024
Firefly Bio Debuts With $94 Million Series A Financing
February 14, 2024
NextPoint Therapeutics Announces Closing of Series B Financing Extension
December 15, 2023
The New Antibodies Revolutionizing Medicine
October 13, 2023
GBR’s USA Life Sciences 2023 Report featuring Chris Bardon
October 10, 2023
AstronauTx Closes $61M Series A to Create New Alzheimer’s Treatments
September 28, 2023
Deka Biosciences Closes USD $20 Million Series B2 Financing
September 21, 2023
The Endpoints 11: Biotech Startups With the Most Exciting Science
September 19, 2023
ReCode Therapeutics Announces Closing of Extension to Series B Financing
August 2, 2023
Reunion Neuroscience Inc. and MPM BioImpact Announce Completion of Plan of Arrangement
April 13, 2023
GBR Connect Series – Interview with Chris Bardon
January 10, 2023
NextPoint Therapeutics Announces $80 Million Series B Financing to Advance Novel Immuno-Oncology Programs
December 8, 2022
Ansbert Gadicke on the Role of Innovation in Biotech
September 9, 2022
Photys Therapeutics Debuts with $75 Million Series A Funding to Advance New Class of Bifunctional Molecules to Modulate and Repair Disease-Driving Proteins
August 25, 2022
Aktis Oncology Raises $84 Million To Advance Novel Targeted Alpha Radiopharmaceuticals
August 16, 2022
Orna Therapeutics: Circular Logic
August 16, 2022
BioImpact Capital Announces Multi-Billion Dollar Landmark Transaction in Vaccines and Cancer
August 16, 2022
Merck and Orna Therapeutics Collaborate to Advance Orna’s Next Generation of RNA Technology
October 1, 2024
AstronauTx Appoints Jane Rhodes as Chief Executive Officer and Expands Executive Team
September 30, 2024
Aktis Oncology Announces $175 Million Oversubscribed Series B Financing
February 23, 2024
Frontier Announces Oversubscribed $80 Million Series C
February 15, 2024
Firefly Bio Debuts With $94 Million Series A Financing
February 14, 2024
NextPoint Therapeutics Announces Closing of Series B Financing Extension
December 15, 2023
The New Antibodies Revolutionizing Medicine
October 10, 2023
AstronauTx Closes $61M Series A to Create New Alzheimer’s Treatments
September 28, 2023
Deka Biosciences Closes USD $20 Million Series B2 Financing
September 21, 2023
The Endpoints 11: Biotech Startups With the Most Exciting Science
September 19, 2023
ReCode Therapeutics Announces Closing of Extension to Series B Financing
August 2, 2023
Reunion Neuroscience Inc. and MPM BioImpact Announce Completion of Plan of Arrangement
January 10, 2023
NextPoint Therapeutics Announces $80 Million Series B Financing to Advance Novel Immuno-Oncology Programs
September 9, 2022
Photys Therapeutics Debuts with $75 Million Series A Funding to Advance New Class of Bifunctional Molecules to Modulate and Repair Disease-Driving Proteins
August 25, 2022
Aktis Oncology Raises $84 Million To Advance Novel Targeted Alpha Radiopharmaceuticals
August 16, 2022
Orna Therapeutics: Circular Logic
August 16, 2022
Merck and Orna Therapeutics Collaborate to Advance Orna’s Next Generation of RNA Technology
April 11, 2024
MPM BioImpact Appoints Frank Neumann, M.D., Ph.D., Distinguished Expert in Clinical Development, as Entrepreneur Partner
February 26, 2024
WSJ: Investors Flock Back to Biotech After a Long, Cold Spell – Featuring Chris Bardon
October 13, 2023
GBR’s USA Life Sciences 2023 Report featuring Chris Bardon
April 13, 2023
GBR Connect Series – Interview with Chris Bardon
December 8, 2022
Ansbert Gadicke on the Role of Innovation in Biotech